SCHEMBL7865484

SCHEMBL7865484

CCS(=O)(=O)c1ccc(C2=C(c3ccc(F)cc3)CCC2)cc1

nearest known ligand 0.71

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 19/20 0.71
PTGS1 P23219 5/20 0.71
MAPK14 Q16539 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8653009 0.87 PTGS2 (0.66) PTGS2PTGS1MAPK14
SCHEMBL8993369 0.86 PTGS2 (0.60) PTGS2PTGS1
SCHEMBL12570643 0.84 PTGS2 (0.58) PTGS2PTGS1
SCHEMBL8993420 0.83 PTGS2 (0.71) PTGS2PTGS1
Sc-57666 SCHEMBL213008 0.83 PTGS2 (1.00) PTGS2PTGS1
Fluoresone SCHEMBL24999 0.82 PSIP1 (0.58) PTGS2
SCHEMBL8993325 0.81 PTGS2 (0.76) PTGS2PTGS1
SCHEMBL6251471 0.81 PTGS2 (0.72) PTGS2PTGS1
SCHEMBL214185 0.79 PTGS2 (1.00) PTGS2PTGS1
SCHEMBL8993482 0.79 PTGS2 (0.77) PTGS2PTGS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1140179-A2 USE OF A CYCLOOXYGENASE 2 INHIBITOR AND AN INTEGRIN ANTAGONIST AS A COMBINATION THERAPY IN THE TREATMENT OF NEOPLASIA G.D. SEARLE & CO. (US) 2001-10-10 EP claimed
WO-2000038786-A2 USE OF CYCLOOXYGENASE 2 INHIBITOR AND AN INTEGRIN ANTAGONIST AS A COMBINATION THERAPY IN THE TREATMENT OF NEOPLASIA G.D. SEARLE & CO. (US) 2000-07-06 WO claimed